Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 903-161-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Dermal Irritation- No irritation or any other effects
Eye Irritation- No irritation or any other effects
Key value for chemical safety assessment
Skin irritation / corrosion
Link to relevant study records
- Endpoint:
- skin corrosion: in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 January 2012 to 04 June 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test system:
- human skin model
- Type of coverage:
- open
- Vehicle:
- unchanged (no vehicle)
- Amount / concentration applied:
- 10 µL
- Duration of treatment / exposure:
- 15 minutes
- Details on study design:
- TEST SYSTEM
- SkinEthic EpiSkin
TEST SITE
- Area of exposure: 0.38 cm2
REMOVAL OF TEST SUBSTANCE
- Washing (if done): washed with >25 mL PBS and tissue paper
- Time after start of exposure: 15 minutes - Irritation / corrosion parameter:
- % tissue viability
- Run / experiment:
- Rep 3, mean of 2 runs
- Value:
- 106.51
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of irritation
- Irritation / corrosion parameter:
- % tissue viability
- Run / experiment:
- Rep 2, mean of 2 runs
- Value:
- 100.29
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of irritation
- Irritation / corrosion parameter:
- % tissue viability
- Run / experiment:
- mean of 3 Reps, positive control
- Value:
- 16.79
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Remarks on result:
- positive indication of irritation
- Irritation / corrosion parameter:
- % tissue viability
- Run / experiment:
- mean of 3 reps, negative control
- Value:
- 100
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Remarks on result:
- no indication of irritation
- Other effects / acceptance of results:
- - OTHER EFFECTS:
- Direct-MTT reduction: EC-903-161-3 was capable of MTT reduction. Therefore, non-viable control
tissues were dosed in parallel with the irritation assay to quantify this effect, and the results were co
rrected accordingly.
DEMONSTRATION OF TECHNICAL PROFICIENCY:
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: met
- Acceptance criteria met for positive control: met
- Acceptance criteria met for variability between replicate measurements:
Three replicates of the positive control, aqueous SDS solution (5%, w/v) (10 µL), and the negative
control, PBS (10 µL) were tested in parallel to demonstrate the efficacy of the assay. The viability of
each individual EpiSkin®tissue was calculated as a percentage of the mean negative control viability
(defined as 100%).
The assay was deemed acceptable if the following criteria were met:
The non-specific MTT reduction was =30% relative to the negative control optical density.
The mean OD value of the 3 negative control tissues was >0.6 and <1.5 and the standard deviation
value (SD) of the % viability was <18%.
The mean % viability of the 3 positive control tissues was <30% and the SD was <18%.
The mean % viability SD of the 3 treated tissues was <18% - Interpretation of results:
- GHS criteria not met
- Conclusions:
- In conclusion, EC-903-161-3 was demonstrated to be non-irritant (no category) when tested in the EpiSkin® in vitro irritation assay.
- Executive summary:
In this study, the irritation potential of EC-903-161-3 was evaluated using the SkinEthic EpiSkin in vitro
irritation assay. Prior to the conduct of the irritation assay, a preliminary test was conducted to assess the
intrinsic ability of the test item to reduce methylthiazoldiphenyl-tetrazolium bromide (MTT) to formazan.
EC-903-161-3 was capable of MTT reduction. Therefore, non-viable control tissues were dosed in
parallel with the irritation assay to quantify this effect, and the results were corrected accordingly. The
dermal irritation potential was assessed by applying an aliquot (10 µL) of the EC-903-161-3 to the
exposed surface of three EpiSkin tissues for 15 min. The surface area of the EpiSkin was 0.38 cm2,
therefore the application rate was 26.3 µL/cm2. After the 15 min exposure period, the test item was
washed from the surface of the EpiSkin tissues using Dulbecco’s phosphate-buffered saline (PBS)
and tissue swabs. The EpiSkin tissues were then incubated for a recovery period of 42 h ± 1 h in a
humidified incubator set to maintain temperature and CO2 levels of 37°C and 5%, respectively. Following
incubation, the EpiSkin tissues were transferred to assay medium containing MTT (0.3 mg/mL) and
returned to the incubator for 3 h. Biopsies of the EpiSkin membranes were then removed, added to
acidified isopropanol, and refrigerated for ca 69 h in order to extract the formazan. The formazan
production (cell viability) was assessed by measuring the optical density of the extracts at a wavelength
of 550 nm. Three replicates of the positive control, aqueous SDS solution (5%, w/v) (10 µL), and the
negative control, PBS (10 µL) were tested in parallel to demonstrate the efficacy of the assay. The
viability of each individual EpiSkin tissue was calculated as a percentage of the mean negative control
viability (defined as 100%). Exposure to EC-903-161-3 resulted in a mean EpiSkin viability of 103.40%
of the negative control value. Exposure to the positive control, aqueous sodium dodecyl sulphate (SDS)
solution (5%, w/v), resulted in a mean EpiSkin viability of 16.79% ± 6.15% of the negative control value.
In conclusion, EC-903-161-3 was demonstrated to be non-irritant (no category) when tested in the
EpiSkin in vitro irritation assay.
Reference
Non-Viable Controls
The mean absorbance value of the three replicate non-viable tissues dosed with EC-903-161-3 was
0.184 ± 0.057. The mean absorbance value of the three replicate undosed non-viable tissues was 0.125
± 0.014. Therefore, the absorbance value for the effect of the unremoved test item was 0.060. This
value was subtracted from the absorbance value of the viable tissues dosed with EC-903-161-3.
Viable Tissues
The absorbance data for one of the tissues dosed with EC-903-161-3 (tissue Replicate 1) were rejected,
due to abnormally high values. Therefore, the mean viability was calculated from the results of the two
accepted tissues. Exposure to EC-903-161-3 resulted in a mean EpiSkin® viability (corrected for the
effect of unremoved test item) of 103.40% of the negative control value.
The standard deviation could not be calculated and the acceptability of the results could not be assessed
on the basis of the acceptance criteria described in Section 7.8 of the report. The results have been
accepted on the following basis:
• The results of the two accepted tissues were similar. The mean viability of the tissues differed by ca 6%.
• The rejection of the results of tissue Replicate 1 represents a “worst case” scenario (i.e. rejection
reduces the mean absorbance value and therefore the mean tissue viability).
Negative Controls
The negative control results were similar for the three viable EpiSkin® tissues dosed with Dulbecco’s
PBS. Exposure to Dulbecco’s PBS resulted in a mean EpiSkin® viability of 100.00% ± 3.57%
Positive Controls
The positive control results were similar for the three viable EpiSkin® tissues dosed with aqueous SDS
solution (5%, w/v). Exposure to aqueous SDS solution (5%, w/v) resulted in a mean EpiSkin® viability
of 16.79% ± 6.15%
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Eye irritation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not irritating)
Respiratory irritation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Dermal Irritation -A study performed on a Registration substance in accordance with the OECD 439 guideline & the ECVAM guidelines, reported no irritancy or any other effects.
Eye Irritation -An in vitro eye irritation study (the HCE in vitro ocular irritation test) that
has undergone ECVAM pre-validation testing was performed on a test material and reported no irritancy or any other effects.
Justification for selection of skin irritation / corrosion endpoint:
Key study conducted in accordance with OECD guideline and GLP standards.
Justification for selection of eye irritation endpoint:
Key study conducted in accordance with OECD guideline and GLP standards.
Justification for classification or non-classification
Dermal Irritation-A study performed on a test material in accordance with the OECD 439 guideline & the ECVAM guidelines, reported no irritancy or any other effects. No classification is therefore warranted under CLP Regulation (EC) 1272/2008.
Eye Irritation- An in vitro skin irritation study (SkinEthic) that has undergone ECVAM pre-validation testing was performed on a test material and reported no irritancy or any other effects. No classification is therefore warranted under CLP Regulation (EC) 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.